论文部分内容阅读
目的研究糖尿病肾病蛋白尿应用前列地尔联合贝那普利治疗的临床效果。方法选择2014年5月至2015年5月收治的200例糖尿病肾病蛋白尿患者,将其均分为两组,对照组100例应用贝那普利治疗,观察组100例在贝那普利治疗的同时应用前列地尔治疗,比较两组患者的治疗效果及并发症发生率。结果两组患者经过治疗后病情均较治疗前有所好转,观察组显效68例,有效30例,无效2例,有效率为98.0%;4例出现并发症,发生率为4.0%。对照组显效42例,有效38例,无效20例,有效率为80.0%;12例出现并发症,发生率为12.0%。两组治疗有效率及并发症发生率比较差异有统计学意义(P<0.05)。结论糖尿病肾病蛋白尿患者运用前列地尔联合贝那普利治疗的临床效果显著,并发症发生率较低,适合临床推广应用。
Objective To study the clinical effect of alprostadil combined with benazepril in the treatment of diabetic nephropathy. Methods 200 diabetic nephropathy patients with proteinuria who were admitted from May 2014 to May 2015 were divided into two groups. 100 cases in the control group were treated with benazepril, and 100 cases in the observation group were treated with benazepril The application of alprostadil treatment at the same time, comparing the two groups of patients with the treatment effect and the incidence of complications. Results After treatment, the two groups of patients were better than before treatment. The observation group was markedly effective in 68 cases, effective in 30 cases and ineffective in 2 cases, the effective rate was 98.0%. The complications occurred in 4 cases, the incidence rate was 4.0%. In the control group, 42 cases were markedly effective, 38 cases were effective, 20 cases were ineffective, and the effective rate was 80.0%. Complications occurred in 12 cases with a rate of 12.0%. The two groups of treatment efficiency and the incidence of complications was significantly different (P <0.05). Conclusion The clinical efficacy of alprostadil combined with benazepril in diabetic nephropathy patients with proteinuria is significant, and the incidence of complications is low, which is suitable for clinical application.